Despite guidance, ctDNA testing adds little benefit to colorectal cancer surveillance (Healio)

A recent study at City of Hope found that adding circulating tumor DNA (ctDNA) testing to standard imaging surveillance for patients with resected stage II–IV colorectal cancer offered minimal clinical benefit. About 30% of recurrences were missed by ctDNA but caught by imaging, and only 1.6% of patients benefitted from ctDNA leading to earlier curative treatment.